Molecure - Clinical trials initiated for second asset
As presented at its R&D day in December 2022, Molecure has now initiated the clinical trial for its second candidate, OATD-02. This Phase I trial is an open-label, multi-centre, first-in-human, dose-escalation study. The company will target cancers where immune checkpoint inhibitors (ICIs) have had limited success, an area where we believe OATD-02/ICI combinations could have an impact. In our view, this milestone supports Molecure’s development strategy and we expect an update on this trial in H223. The company also has pre-clinical animal model data for OATD-01 for the treatment of sarcoidosis, which suggests potential use in non-alcoholic steatohepatitis, a fibrotic disease with unmet need.OncoArendi Therapeutics SA (OAT) is a Poland-based biopharmaceutical company dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Companys business model is strictly focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations with the key opinion leaders in specific disease areas.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.